Skip to content
Lonza
-
Lonza expands into Pure-Play CDMO with massive dual biologics expansion
The company has announced plans to expand its antibody-drug conjugate (ADC) manufacturing capabilities in Switzerland while also broadening its long-term partnership with a leading, though undisclosed, U.S.-based biopharmaceutical company.
-
Lonza completes CDMO pivot with USD3B sale of capsule business to Lone Star
The company also secured additional preferential participation in future exit proceeds, though these returns depend on Lone Star first recovering its initial equity investment.